Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Mind Medicine (MindMed) Inc. (E:MMED)

Business Focus: Biotechnology & Medical Research (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for MMED within the last 6 months
See all filings within the past 6 months

Company News

Mar 09, 2023 16:02 ET
MindMed Reports Full Year 2022 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the full-year ended December 31, 2022.
Read full article
Feb 28, 2023 07:30 ET
MindMed to Participate in March Investor Conferences
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences:
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 202394,062-4,001
Feb 28, 202398,0637,361
Feb 15, 202390,702-66,636
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of drug candidates, targeting the serotonin, dopamine and acetylcholine systems. This specifically includes pharmaceutically optimized drug products derived from the psychedelic and empathogen drug classes, including lysergic acid diethylamide (LSD), R(-)-methylenedioxymethamphetamine (MDMA) and zolunicant, or 18-methoxycoronaridine (MC), a congener of ibogaine. The Company's subsidiaries include Mind Medicine, Inc. (MindMed US), HealthMode, Inc., MindMed Pty Ltd., and MindMed GmbH.

See business summary



Search (past week) for $MMED.CA

  • No tweets found